Global Drug Discovery Services Market Poised for Transformative Growth, Projected to Reach USD 76.5 Billion by 2033

The global drug discovery services market is set to undergo a remarkable transformation, with an estimated valuation of USD 76.5 billion by 2033, according to a comprehensive market analysis released today. This projection indicates a substantial increase from the anticipated USD 19.7 billion valuation in 2023, reflecting an impressive compound annual growth rate (CAGR) of 14.5% over the next decade.

The driving force behind this significant growth is the escalating demand for innovative therapies to combat chronic diseases. As chronic illnesses become increasingly prevalent worldwide, the urgency for novel treatment solutions has intensified, creating a fertile landscape for advancements in drug discovery services.

“Investments in research and development (R&D) are surging, fueled by unmet medical needs across various therapeutic domains,” stated a representative from Future Market Insights (FMI). “This trend underscores a pivotal moment for the pharmaceutical sector, where innovation and technological advancements are crucial in meeting evolving healthcare challenges.”

Technological breakthroughs, particularly in mass spectrometry for oncology drug development, are revolutionizing the drug discovery process. These innovations not only enhance the efficiency of drug discovery but also accelerate the timelines for bringing new therapies to market, ensuring that patients have timely access to vital treatments.

The optimistic forecast for the drug discovery services market reflects a promising future driven by the convergence of escalating chronic disease burdens, unmet medical needs, and continuous technological innovations. The stage is set for exceptional growth and innovation in the years ahead, positioning the pharmaceutical industry as a vital player in addressing global health challenges.

Key Takeaways from Drug Discovery Services Market:

• In 2022, the global drug discovery services market size stood at USD 17.5 billion.
• The pharmaceutical companies segment accounted for 42% market share in 2022.
• In terms of market share, the Hit-to-lead identification method is the dominant segment.
• During the projection period, the biological services segment in the market is expected to increase at a high CAGR.
• The oncology segment accounted for an impressive 39.7% market share in 2022.
• North America accounted for a massive 35.2% market share in 2022.

Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!

Recent Developments Observed by FMI:

• Genentech announced in January 2023 that it had been granted Priority Review and Fast Track designation for Glofitamab. To treat adult patients with refractory or relapsing LBCL, the medication, a new bispecific antibody, activates immune system T-cells.
• Brexpiprazole, an atypical antipsychotic supplement NDA authorized for schizophrenia, was released in January 2023 under FDA Priority Review. Brexpiprazole was developed by H. Lundbeck A/S and Otsuka Pharmaceuticals.
• The FDA approved UCB’s Rozanolixizumab for additional Phase III research in January 2023.
• Harm Reduction Therapeutics announced about RiVive in December 2022. As the FDA accepted and awarded Priority for Review to their new drug application. The product is an over-the-counter nasal spray form of naloxone.

Key Players in the Market:

• Laboratory Corporation of America Holdings
• Charles River Laboratories International Inc.
• Genscript Biotech Corporation
• Thermo Fisher Scientific Inc.
• Pharmaron Beijing Co. Ltd.
• Evotec SE
• Eurofins Scientific SE
• Pharmaceutical Product Development Inc.
• Piramal Enterprise Limited
• Syngene International Limited

Market Segmentation:

By Process:

• Target Selection
• Target Validation
• Hit-to-lead identification
• Lead Optimization
• Candidate Validation

By Type:

• Chemistry Services
• Biology Services

By Drug Type:

• Small Molecule Drugs
• Biologics Drugs

By Therapeutic Area:

• Neurology
• Infectious and Immune Systems Diseases
• Digestive System Diseases
• Oncology
• Other Therapeutic Areas

By End User:

• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• Manufacturing
• Other End Users

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• The Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube